Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a recently recognized neurodegenerative condition defined by the accumulation of phosphorylated TDP-43 protein in limbic brain regions, often co-occurring with Alzheimer's disease pathology but representing a distinct clinicopathological entity. [1][2]
LATE primarily affects episodic memory, with semantic memory decline also common. Patients present with gradual memory loss that may be initially indistinguishable from Alzheimer's disease.
The progression of LATE is generally slower than typical Alzheimer's disease, with survival times often exceeding 5-7 years from symptom onset.
LATE frequently co-exists with Alzheimer's disease (AD) pathology, and the combination of both pathologies results in more severe cognitive impairment than either alone. However, LATE can also occur in the absence of significant amyloid or tau pathology. [3]
The co-occurrence of LATE and AD pathology represents a common mixed dementia phenotype, particularly in oldest-old individuals.
LATE is characterized by neuronal and glial inclusions containing phosphorylated TDP-43, primarily affecting the limbic system and adjacent temporal lobe structures.
The staging of LATE follows a predictable pattern: beginning in the amygdala, progressing to hippocampus, then to entorhinal cortex and inferior temporal gyrus.
Hippocampal atrophy on structural MRI is a key finding, though pattern may differ from typical AD.
Emerging evidence supports CSF and blood biomarkers for TDP-43 pathology, though these are not yet standardized for clinical use.
LATE is now recognized as one of the most common neurodegenerative pathologies in older adults, affecting approximately 10-25% of individuals over age 80. [4] Autopsy studies consistently demonstrate that TDP-43 pathology in the limbic system is present in a substantial proportion of cognitively impaired elderly individuals, often alongside Alzheimer's disease changes.
The age-dependent increase in prevalence distinguishes LATE from many other neurodegenerative conditions, with the "oldest-old" (those over 90) showing the highest burden. [5]
Current evidence suggests a slight female predominance in LATE, though this may reflect survival bias and the greater longevity of women in affected age cohorts. [6]
The APOE ε4 allele represents the strongest known genetic risk factor for LATE, with carriers showing approximately 2-3 fold increased risk. [7] Interestingly, the APOE ε2 allele may confer protection against LATE pathology.
Loss-of-function mutations in the GRN gene cause familial frontotemporal dementia and are associated with TDP-43 pathology. Common genetic variants near GRN may influence LATE risk. [8]
Genome-wide association studies have identified several additional risk loci, including variants in:
Cerebrovascular disease, including small vessel disease and white matter hyperintensities, appears to increase LATE risk. The presence of vascular pathology may interact with TDP-43 to accelerate cognitive decline.
History of traumatic brain injury has been suggested as a potential risk factor, though evidence remains preliminary.
Higher education and greater cognitive reserve may provide some protection, potentially by delaying the clinical manifestation of LATE pathology.
The 2023 consensus criteria for LATE staging establish a clinical-pathological framework: [10]
Plasma p-tau181 and p-tau217 show promise for distinguishing LATE from AD, with lower levels in LATE compared to pure AD cases.
LATE must be distinguished from:
There are no disease-modifying treatments specifically approved for LATE. Current management focuses on:
Given the role of neuroinflammation in LATE pathogenesis:
As of 2024, no large-scale Phase 3 trials are specifically targeting LATE. However, several trials for related conditions may provide insights:
Nelson et al. LATE-NC: A New Age-Related Disease (Brain, 2019). 2019. ↩︎
Buciuc et al. LATE Clinical Features (Neurology, 2023). 2023. ↩︎
Robinson et al. LATE and AD Co-Pathology (Acta Neuropathol, 2022). 2022. ↩︎
Meehan et al. LATE Prevalence in Community-Based Cohorts (Acta Neuropathol, 2024). 2024. ↩︎
Kaufman et al. LATE in the Oldest-Old (Neurology, 2023). 2023. ↩︎
Agrawal et al. Sex Differences in LATE Pathology (J Neuropathol Exp Neurol, 2024). 2024. ↩︎
Yang et al. APOE and LATE Risk (Neurology, 2022). 2022. ↩︎
Chen-Plotkin et al. TMEM106B and TDP-43 Pathology (Brain, 2022). 2022. ↩︎
Zhang et al. TMEM106B Genetic Variants in LATE (Acta Neuropathol Commun, 2023). 2023. ↩︎
Nelson et al. LATE Consensus Diagnostic Criteria 2023 (Brain, 2023). 2023. ↩︎
Fergiusdottir et al. CSF p-TDP-43 as LATE Biomarker (Neurology, 2024). 2024. ↩︎
Liu et al. TDP-43 Aggregation Inhibitors (Nat Neurosci, 2024). 2024. ↩︎